Lev Pharmaceuticals is focused on developing therapeutic products for the treatment of inflammatory diseases. Founded by Joshua D. Schein and Judson A. Cooper in 2003, Lev Pharmaceuticals is backed by investors that include Emigrant Capital, Hound Partners, Mast Capital Management, Rosalind Capital Partners, and Southpoint Capital Advisors and is headquartered in New York.